PE11562009A1 - Salts (3 - {[[3- (6-amino-2-butoxy-8-oxo-7,8-dihydro-9 H -purin-9-yl) propyl] (3-morpholin-4-ylpropyl) amino] methyl} phenyl) acetate - Google Patents

Salts (3 - {[[3- (6-amino-2-butoxy-8-oxo-7,8-dihydro-9 H -purin-9-yl) propyl] (3-morpholin-4-ylpropyl) amino] methyl} phenyl) acetate

Info

Publication number
PE11562009A1
PE11562009A1 PE0020772008A PE0020772008A PE11562009A1 PE 11562009 A1 PE11562009 A1 PE 11562009A1 PE 0020772008 A PE0020772008 A PE 0020772008A PE 0020772008 A PE0020772008 A PE 0020772008A PE 11562009 A1 PE11562009 A1 PE 11562009A1
Authority
PE
Peru
Prior art keywords
amino
ylpropyl
purin
morpholin
butoxy
Prior art date
Application number
PE0020772008A
Other languages
Spanish (es)
Inventor
Thomas Mcinally
Hakan Schulz
Original Assignee
Astrazeneca Ab
Dainippon Sumitomo Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US1416407P priority Critical
Application filed by Astrazeneca Ab, Dainippon Sumitomo Pharma Co filed Critical Astrazeneca Ab
Publication of PE11562009A1 publication Critical patent/PE11562009A1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40795767&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE11562009(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulfur or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18Heterocyclic compounds containing purine ring systems with oxygen, sulfur or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Abstract

SE REFIERE A UNA SAL DE ACIDO CLORHIDRICO, ACIDO BROMHIDRICO O ACIDO MALEICO DE (3-{[[3-(6-AMINO-2-BUTOXI-8-OXO-7,8-DIHIDRO-9H-PURIN-9-IL)PROPIL](3-MORFOLIN-4-ILPROPIL)AMINO]METIL}FENIL)ACETATO DE METILO TALES COMO MONOCLORHIDRATO, MONOBROMHIDRATO, Y DIMALEATO DE (3-{[[3-(6-AMINO-2-BUTOXI-8-OXO-7,8-DIHIDRO-9H-PURIN-9-IL)PROPIL](3-MORFOLIN-4-ILPROPIL)AMINO]METIL}FENIL)ACETATO DE METILO. It refers to a hydrochloric acid salt, hydrobromic acid or maleic (3 - {[[3- (6-AMINO-2-butoxy-8-oxo-7,8-dihydro-9H-PURIN-9-YL) propyl] (3-morpholin-4-ylpropyl) amino] methyl} phenyl) acetate SUCH AS monohydrochloride, monohydrobromide, Y dimaleate (3 - {[[3- (6-AMINO-2-butoxy-8-oxo- 7,8-dihydro-9H-PURIN-9-yl) propyl] (3-morpholin-4-ylpropyl) amino] methyl} phenyl) acetate. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE ESTA EN FORMA DE UNA FORMULACION DE POLVO SECO QUE CONTIENE DICHAS SALES PARA UNA TERAPIA INHALATORIA SIENDO UTIL PARA EL TRATAMIENTO DE ASMA, RINITIS ALERGICA, DERMATITIS ATOPICA, DERMATOSIS ALSO REFERS TO A PHARMACEUTICAL COMPOSITION IS as a dry powder formulation containing such SALES REMAIN FOR inhalation therapy useful for the treatment of asthma, rhinitis ALLERGIC, Dermatitis Atopic DERMATOSIS
PE0020772008A 2007-12-17 2008-12-15 Salts (3 - {[[3- (6-amino-2-butoxy-8-oxo-7,8-dihydro-9 H -purin-9-yl) propyl] (3-morpholin-4-ylpropyl) amino] methyl} phenyl) acetate PE11562009A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US1416407P true 2007-12-17 2007-12-17

Publications (1)

Publication Number Publication Date
PE11562009A1 true PE11562009A1 (en) 2009-09-03

Family

ID=40795767

Family Applications (1)

Application Number Title Priority Date Filing Date
PE0020772008A PE11562009A1 (en) 2007-12-17 2008-12-15 Salts (3 - {[[3- (6-amino-2-butoxy-8-oxo-7,8-dihydro-9 H -purin-9-yl) propyl] (3-morpholin-4-ylpropyl) amino] methyl} phenyl) acetate

Country Status (24)

Country Link
US (1) US8673907B2 (en)
EP (1) EP2235018A4 (en)
JP (1) JP5557748B2 (en)
KR (2) KR20160085360A (en)
CN (1) CN101903389B (en)
AR (1) AR069780A1 (en)
AU (1) AU2008339095B2 (en)
BR (1) BRPI0821020A2 (en)
CA (1) CA2709126C (en)
CO (1) CO6280403A2 (en)
CR (1) CR11507A (en)
CU (1) CU23932B1 (en)
EA (1) EA017532B1 (en)
EC (1) ECSP10010265A (en)
HN (1) HN2010001235A (en)
IL (1) IL206039D0 (en)
NZ (1) NZ585961A (en)
PE (1) PE11562009A1 (en)
SV (1) SV2010003596A (en)
TW (1) TWI424848B (en)
UA (1) UA100996C2 (en)
UY (1) UY31531A1 (en)
WO (1) WO2009078798A1 (en)
ZA (1) ZA201003877B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005226359B2 (en) 2004-03-26 2011-02-03 Astrazeneca Aktiebolag 9-substituted 8-oxoadenine compound
TW200831105A (en) 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
WO2008114006A1 (en) 2007-03-19 2008-09-25 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators
EP2132209B8 (en) 2007-03-19 2014-04-16 AstraZeneca AB 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators
JPWO2008114819A1 (en) 2007-03-20 2010-07-08 大日本住友製薬株式会社 New adenine compound
PE12362009A1 (en) 2007-11-22 2009-09-16 Astrazeneca Ab Pyrimidine derivatives as immunomodulators TLR7
WO2009091031A1 (en) * 2008-01-17 2009-07-23 Dainippon Sumitomo Pharma Co., Ltd. Method for producing adenine compound
CA2711769A1 (en) * 2008-01-17 2009-07-23 Dainippon Sumitomo Pharma Co. Ltd. Method for preparing adenine compound
DK2324026T3 (en) 2008-08-11 2015-09-21 Glaxosmithkline Llc Purine derivatives for use in the treatment of allergic, in-inflammatory and infectious diseases
ES2467108T3 (en) * 2008-12-09 2014-06-11 Gilead Sciences, Inc. Modulators of toll-like receptors
GB0908772D0 (en) 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
NZ598933A (en) 2009-10-22 2013-04-26 Gilead Sciences Inc Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
JP5922587B2 (en) * 2010-02-10 2016-05-24 グラクソスミスクライン エルエルシー 6-amino -2 - {[(1s) -1- methylbutyl] oxy} -9- [5- (1-piperidinyl) pentyl] -7,9-dihydro -8h- purin-8-one maleate
JP5978225B2 (en) 2010-12-16 2016-08-24 大日本住友製薬株式会社 Useful imidazo [4,5-c] quinolin-1-yl derivatives to treat
ES2627433T3 (en) 2010-12-17 2017-07-28 Sumitomo Dainippon Pharma Co., Ltd. Purine derivatives
CA2841361A1 (en) 2011-07-22 2013-01-31 Glaxosmithkline Llc Composition for the treatment of allergic diseases and inflammatory conditions
JP6184423B2 (en) 2012-05-18 2017-08-23 大日本住友製薬株式会社 Carboxylic acid compound
AR092198A1 (en) 2012-08-24 2015-04-08 Glaxosmithkline Llc Pyrazolopyrimidines derivatives
KR20150085081A (en) 2012-11-20 2015-07-22 글락소스미스클라인 엘엘씨 Novel compounds
PT2922549T (en) 2012-11-20 2017-09-01 Glaxosmithkline Llc Novel compounds
CA2890201A1 (en) 2012-11-20 2014-05-30 Glaxosmithkline Llc Novel compounds

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1375162A (en) 1970-10-22 1974-11-27
US3832460A (en) * 1971-03-19 1974-08-27 C Kosti Anesthetic-vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue
GB1546937A (en) 1976-07-29 1979-05-31 Beecham Group Ltd 2,4-diaminopyrimidine derivatives
DK161312C (en) * 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade for preparing 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridine-3,5-dicarboxylic acid esters or acid addition salts thereof as well as phthalimidoderivater for use as starting material in the process
HU201675B (en) * 1983-08-26 1990-12-28 Ivan Balkanyi Process for producing oral pharmaceutical compositions with unappetizing effect
SE8404768L (en) 1983-09-27 1985-03-28 Ceskoslovenska Akademie Ved 9- (aminoalkyl) -8-hydroxiadeniner seen and their front tell accession
ZA8408968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
IL78643D0 (en) 1985-05-02 1986-08-31 Wellcome Found Purine derivatives,their preparation and pharmaceutical compositions containing them
DE3603577A1 (en) 1986-02-06 1987-08-13 Joachim K Prof Dr Seydel Novel substituted 2,4-diamino-5-benzylpyrimidines, their preparation and their use as medicaments having antibacterial activity
AU4673993A (en) * 1992-07-28 1994-02-14 Procter & Gamble Company, The Pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether
US5543407A (en) * 1992-09-30 1996-08-06 Ningbo Institute Of Microcirculation And Henbane Preparation and application of scopolamine and chlorpromazine as a drug-withdrawal agent
JPH08165292A (en) 1993-10-07 1996-06-25 Boryung Pharm Co Ltd Adenine derivative, its production and use
DE122010000050I2 (en) * 1994-03-02 2011-07-21 Organon Nv Sublingual or buccal drug.
US6110923A (en) 1994-06-22 2000-08-29 Biochem Pharma Inc. Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity
WO1996011200A1 (en) 1994-10-05 1996-04-18 Chiroscience Limited Purine and guanine compounds as inhibitors of pnp
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
WO1998001448A1 (en) 1996-07-03 1998-01-15 Japan Energy Corporation Novel purine derivatives
US6624138B1 (en) * 2001-09-27 2003-09-23 Gp Medical Drug-loaded biological material chemically treated with genipin
CA2212449C (en) * 1997-08-07 2001-11-06 Brantford Chemicals Inc. Improved preparation of 1,2,5,6-tetrahydro-3-carboalkoxypyridines such as arecoline and salts of 1,2,5,6-tetrahydro-3-carboalkoxypyridines and arecoline hydrobromide
NZ504800A (en) 1997-11-28 2001-10-26 Sumitomo Pharma 6-Amino-9-benzyl-8-hydroxy-purine derivatives and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases thereof
JPH11179507A (en) 1997-12-17 1999-07-06 Kawasaki Steel Corp Method for oscillating mold for continuous casting
JPH11187245A (en) 1997-12-17 1999-07-09 M Ken:Kk Digital image processing method, digital image processor and recording medium with digital image processing program recorded thereon
JPH11180981A (en) 1997-12-19 1999-07-06 Japan Energy Corp Heterocyclic derivative
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
JP4160645B2 (en) 1997-12-24 2008-10-01 大日本住友製薬株式会社 New adenine derivatives and their pharmaceutical use
JP4189048B2 (en) 1997-12-26 2008-12-03 大日本住友製薬株式会社 Heterocyclic compounds
WO2000012487A1 (en) 1998-08-27 2000-03-09 Sumitomo Pharmaceuticals Co., Ltd. Pyrimidine derivatives
JP2000159767A (en) 1998-11-26 2000-06-13 Japan Energy Corp New production process for 8-hydroxyadenine derivative
CZ27399A3 (en) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituted nitrogen heterocyclic derivatives process of their preparation, the derivatives employed as medicaments, pharmaceutical composition and a compound pharmaceutical preparation in which these derivatives are comprised as well as use of these derivatives for preparing medicaments
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
BR0111889A (en) * 2000-06-20 2003-06-24 Atherogenics Inc 1,3-bis- (substituted-phenyl) -2-propen-1-ones and their use to treat disorders mediated by VCAM-1
US20020040032A1 (en) 2000-07-07 2002-04-04 Glasky Michelle S. Methods for stimulation of synthesis of synaptophysin in the central nervous system
AU7186701A (en) 2000-07-07 2002-01-21 Neotherapeutics Inc Methods for treatment of conditions affected by activity of multidrug transporters
DE60144123D1 (en) 2000-07-07 2011-04-07 Spectrum Pharmaceuticals Inc A method for treating drug-induced peripheral neuropathy and related forms of disease
US6887880B2 (en) 2000-11-20 2005-05-03 Millennium Pharmaceuticals, Inc. Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions, and method of use thereof
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
AT404561T (en) 2001-04-17 2008-08-15 Dainippon Sumitomo Pharma Co new adenine
IN192057B (en) * 2001-07-19 2004-02-14 Ranbaxy Lab Ltd Process for the preparation of pure citalopram hydrobromide
ITRM20010465A1 (en) 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Triazolyl-imidazopyridine derivatives and triazolilpurine useful as ligands of the adenosine A2A receptor and their use as medicam
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20060252774A1 (en) 2002-05-02 2006-11-09 Vatner Stephen F Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases
US7115373B2 (en) 2002-06-27 2006-10-03 Genox Research, Inc. Method of testing for atopic dermatitis by measuring expression of the NOR-1 gene
US20050261355A1 (en) * 2002-06-27 2005-11-24 Sb Pharmco Puerto Rico Inc., Carvedilol hydobromide
AU2003208084A1 (en) 2002-07-30 2004-02-16 Sankyo Co., Ltd Phosmidosine derivative and process for producing the same
US7754728B2 (en) 2002-09-27 2010-07-13 Dainippon Sumitomo Pharma Co., Ltd. Adenine compound and use thereof
JP2004137157A (en) 2002-10-16 2004-05-13 Sumitomo Pharmaceut Co Ltd Medicine comprising new adenine derivative as active ingredient
US7444183B2 (en) * 2003-02-03 2008-10-28 Enteromedics, Inc. Intraluminal electrode apparatus and method
EA200600069A1 (en) 2003-06-20 2006-08-25 Коли Фармасьютикал Гмбх Low-molecular antagonists of toll-similar receptors (tlr)
EA200600540A1 (en) * 2003-09-05 2006-08-25 Анадис Фармасьютикалз, Инк. Introduction of tlr7 ligands and their treatments for the treatment of hepatitis c virus infection
JP2005089334A (en) 2003-09-12 2005-04-07 Sumitomo Pharmaceut Co Ltd 8-hydroxyadenine compound
ITMI20040146A1 (en) * 2004-01-30 2004-04-30 Acraf Ibopamine maleate method for preparing it and pharmaceutical compositions that comprise
JPWO2005092892A1 (en) 2004-03-26 2008-02-14 大日本住友製薬株式会社 8-oxo-adenine compound
AU2005226359B2 (en) * 2004-03-26 2011-02-03 Astrazeneca Aktiebolag 9-substituted 8-oxoadenine compound
KR20070012675A (en) * 2004-04-20 2007-01-26 사노피-아벤티스 Polymorphic forms of methyl (+)-(s)-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4h) acetate hydrobromide, clopidogrel hydrobromide
WO2006117670A1 (en) 2005-05-04 2006-11-09 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c
EP1908480A4 (en) 2005-06-03 2009-07-01 Riken Interferon- alpha regulator
US7645802B2 (en) * 2005-06-27 2010-01-12 Biovail Laboratories International Srl. Bupropion hydrobromide and therapeutic applications
US20090324551A1 (en) 2005-08-22 2009-12-31 The Regents Of The University Of California Office Of Technology Transfer Tlr agonists
TW200801003A (en) 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
US20090105212A1 (en) 2005-09-22 2009-04-23 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
EP1939200A4 (en) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co Novel adenine compound
WO2007034881A1 (en) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. Novel adenine compound
US20090118263A1 (en) 2005-09-22 2009-05-07 Dainippon Sumitomo Pharma Co., Ltd. Novel Adenine Compound
TW200745114A (en) 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
US20080269240A1 (en) 2005-09-22 2008-10-30 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel Adenine Compound
CN102336702B (en) * 2005-11-08 2015-02-11 米伦纽姆医药公司 Pharmaceutical salts and polymorphs of a factor XA inhibitor n-(5-chloro-pyridin-2-yl)-2-(4-cyano-benzoyl-amino)-5-methoxy-benzamide hydrochloride
WO2007076157A2 (en) * 2005-12-27 2007-07-05 Teva Pharmaceuticals Industries Ltd. Processes for preparing darifenacin hydrobromide
KR20080085232A (en) 2006-02-17 2008-09-23 화이자 리미티드 3-deazapurine derivatives as tlr7 modulators
US20090281075A1 (en) 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
US8138172B2 (en) 2006-07-05 2012-03-20 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of TLR7
AR061839A1 (en) 2006-07-07 2008-09-24 Gilead Sciences Inc Compounds and pharmaceutical compositions that selectively activate toll-like receptors 7 (TLR7), and use thereof as antiviral agents
AU2007286051B2 (en) * 2006-08-10 2013-01-10 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure
HU0600868A3 (en) * 2006-11-24 2009-03-30 Richter Gedeon Nyrt 5-{2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2h-indol-2-one hydrogen bromide polimorphs and process for their preparation
JP5464584B2 (en) * 2006-12-06 2014-04-09 ヤンセン・アールアンドデイ・アイルランド Hydrobromide anti hiv compound
TW200831105A (en) 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
US20080176905A1 (en) * 2007-01-22 2008-07-24 Santiago Ini Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof
PT2125792E (en) 2007-02-19 2011-03-01 Glaxosmithkline Llc Purine derivatives as immunomodulators
EP2132209B8 (en) 2007-03-19 2014-04-16 AstraZeneca AB 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators
WO2008114006A1 (en) 2007-03-19 2008-09-25 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators
PE18872008A1 (en) 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co New adenine compound
JPWO2008114819A1 (en) 2007-03-20 2010-07-08 大日本住友製薬株式会社 New adenine compound
EP2093224A1 (en) * 2007-05-01 2009-08-26 Plus Chemicals B.V. Process for preparing eletriptan hydrobromide form beta
MY150519A (en) 2007-05-08 2014-01-30 Astrazeneca Ab Imidazoquinolines with immuno-modulating properties
AR067182A1 (en) 2007-06-29 2009-09-30 Gilead Sciences Inc 7 toll receptor modulators type
PE12362009A1 (en) 2007-11-22 2009-09-16 Astrazeneca Ab Pyrimidine derivatives as immunomodulators TLR7
WO2009091031A1 (en) * 2008-01-17 2009-07-23 Dainippon Sumitomo Pharma Co., Ltd. Method for producing adenine compound
CA2711769A1 (en) * 2008-01-17 2009-07-23 Dainippon Sumitomo Pharma Co. Ltd. Method for preparing adenine compound
CN101239980B (en) 2008-02-18 2011-06-22 靳广毅 Immunity receptor regulator couplet precursor, couplet and application thereof
WO2009151910A2 (en) 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
DK2324026T3 (en) 2008-08-11 2015-09-21 Glaxosmithkline Llc Purine derivatives for use in the treatment of allergic, in-inflammatory and infectious diseases
GB0908772D0 (en) 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
JP2013512859A (en) 2009-12-03 2013-04-18 大日本住友製薬株式会社 Imidazoquinoline acting through Toll-like receptors (tlr)

Also Published As

Publication number Publication date
TWI424848B (en) 2014-02-01
EP2235018A1 (en) 2010-10-06
UA100996C2 (en) 2013-02-25
EP2235018A4 (en) 2012-02-15
CA2709126C (en) 2016-12-13
US20110294802A1 (en) 2011-12-01
SV2010003596A (en) 2011-02-07
CU23932B1 (en) 2013-07-31
CO6280403A2 (en) 2011-05-20
IL206039D0 (en) 2010-11-30
EA017532B1 (en) 2013-01-30
EA201001014A1 (en) 2011-02-28
CN101903389A (en) 2010-12-01
KR20160085360A (en) 2016-07-15
WO2009078798A1 (en) 2009-06-25
BRPI0821020A2 (en) 2015-06-16
TW200934498A (en) 2009-08-16
CU20100123A7 (en) 2011-10-14
CN101903389B (en) 2013-04-17
JP2011506598A (en) 2011-03-03
US8673907B2 (en) 2014-03-18
CR11507A (en) 2010-07-15
ECSP10010265A (en) 2010-07-30
HN2010001235A (en) 2013-02-11
CA2709126A1 (en) 2009-06-25
ZA201003877B (en) 2011-02-23
UY31531A1 (en) 2009-08-03
AU2008339095A1 (en) 2009-06-25
AU2008339095B2 (en) 2012-05-03
NZ585961A (en) 2012-05-25
JP5557748B2 (en) 2014-07-23
AR069780A1 (en) 2010-02-17
KR20100093566A (en) 2010-08-25

Similar Documents

Publication Publication Date Title
AU2012296639B2 (en) Substituted (E)-N'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors
JO3146B1 (en) Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders
WO2008055870A8 (en) Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
MY155275A (en) 4-(4-[6-(trifluoromethyl-pyridin-3-ylamino)-n-containing-heteroaryl]-phenyl)-cyclohexyl)-acetic acid derivatives and pharmaceutical uses thereof
BRPI0711121A2 (en) substituted benzonitrile derivatives glucopiranosila, pharmaceutical compositions containing such compounds, their use and process for its manufacturing
AR084824A1 (en) Isoquinolinones and processes for preparing solid forms of isoquinolinones
CL2013000024A1 (en) heterocyclic compounds; plagicida quelos composition contains; method for controlling pests; and intermediate compounds.
BR112014003681A2 (en) compound, pharmaceutical composition, pharmaceutical combination product, use of a compound and method for treating diseases or conditions
CR11019A (en) 3-imidazolyl-indoles for the treatment of proliferative diseases
UY32799A (en) Oxazine derivatives and their use in treating neurological disorders
WO2008106128A3 (en) CYCLIC UREA AND CARBAMATE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1
CL2008000404A1 (en) crystalline napadisylate salt of 5- (2 - [[6- (2,2-difluoro-2-phenylethoxy) hexyl] amino] -1-hydroxyethyl) -8-hydroxyquinolin-2 (1H) -one; pharmaceutical composition; Pharmaceutical combination; and use in the treatment of diseases such as asthma or COPD.
PE16912009A1 (en) Inhalation formulation comprising aclidinium
GT201200250A (en) Ariltriazolonas linked to bisaryl and use
WO2009138386A3 (en) Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
TWI648277B (en) Examples of the heterocyclic amine inhibitors are pi3k
CL2016000212A1 (en) Compounds derived from alkyl esters of aryl 4-amino picolinic acids; herbicidal composition comprising said compounds; and method for controlling undesirable vegetation.
CO6321265A2 (en) Compounds 2-amido-3-methyl phenyl -substituted pyrimidinone pyrrolo BACE-1 inhibitors as compositions and their use
Hashimoto Glycine transport inhibitors for the treatment of schizophrenia
WO2010046445A3 (en) Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use
UY30804A1 (en) Nicotinamide derivatives, salts and solvates thereof, compositions containing them and applications pharmaceutical
BR112014000371A2 (en) trifluoromethyl-oxadiazole derivatives and the use thereof in treating disease
WO2011126808A3 (en) Pharmacologically induced transgene ablation system
ECSP11010980A (en) spiro fused heteroaromatic compounds for treating bacterial infections
NZ601126A (en) Voltage-gated sodium channel blockers

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed